Humedics
Humedics is a Berlin-based medical technology company that sells the LiMAx breath test, a non-invasive, real-time diagnostic for measuring dynamic liver function. It serves hepatology, liver surgery, transplant, and oncology departments at university hospitals across Germany, Austria, the UK, and now Switzerland.
- Company typePrivate
- Founded2009
- HeadquartersBerlin, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Humedics does
Humedics GmbH is a Berlin-based medical technology company founded in 2009 that develops and commercializes the LiMAx test, a non-invasive diagnostic for measuring dynamic liver function capacity in real time. The test uses a 13C-methacetin breath assay analyzed by the company's proprietary FLIP detection devices (currently sold in FLIP 4.0 and FLIP 2.0 versions, both CE marked for the European market) to deliver quantitative liver function results within minutes, in contrast to static blood markers. Clinical applications span liver surgery (preoperative risk assessment for post-hepatectomy liver failure), liver transplantation, hepatology (fibrosis, cirrhosis, and chronic liver disease staging), and oncology (treatment selection and monitoring for hepatocellular carcinoma and other liver tumors).
The company operates a B2B enterprise sales model targeting university hospitals and major medical centers, with documented routine clinical use at more than 30 leading European university hospitals and over 20,000 LiMAx tests performed cumulatively. Commercial geographies currently cover Germany, Austria, and the United Kingdom, with Switzerland added in January 2026 following the inclusion of the LiMAx test in the TARDOC outpatient reimbursement tariff at approximately €970 per test. The marketing approach is evidence-driven, leaning heavily on more than 70 peer-reviewed publications, clinical-guideline inclusion (the 2023 E-AHPBA-ESSO-ESSR Innsbruck consensus), recurring expert workshops, and a quarterly literature service aimed at hepatologists, hepatobiliary and transplant surgeons, and oncologists. Revenue is generated primarily through hardware sales of FLIP devices plus per-test consumables tied to clinical volume, with reimbursement now codified in the Swiss outpatient tariff system.
Humedics firmographics
Firmographics- Name
- Humedics
- Legal name
- Humedics GmbH
- Website
- https://humedics.eu
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Humedics is a Berlin-based medical technology company that sells the LiMAx breath test, a non-invasive, real-time diagnostic for measuring dynamic liver function. It serves hepatology, liver surgery, transplant, and oncology departments at university hospitals across Germany, Austria, the UK, and now Switzerland.
- Ownership category
- akta.pro rank
Humedics industry classification
Industry- Product category
- Liver Function Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Hepatology & Liver Disease (HLAKAEAB)
Keywords
Where Humedics is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Humedics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- LiMAx Test System Sales: Humedics generates revenue through the sale of the LiMAx test system, including the FLIP detection device. Tests are performed at clinical sites, with reimbursement rates varying by market. The company has achieved TARDOC reimbursement of approximately €970 per test in Switzerland's outpatient sector as of January 2026.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Switzerland outpatient TARDOC reimbursement |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Humedics product offering
Product offeringCore offering
Humedics develops and sells the LiMAx test system, a non-invasive breath-based diagnostic that quantitatively measures dynamic liver function capacity in real time. The offering combines the 13C-methacetin breath test assay with the FLIP detection device (available as FLIP 4.0 and FLIP 2.0) and is CE marked for the European market, sold to university hospitals and medical centers for use in liver surgery, transplantation, hepatology, and oncology.
Product overview
Humedics offers the LiMAx test system, a medical diagnostic platform for rapid and accurate liver function measurement. The system consists of the LiMAx breath test (the core diagnostic assay) and the LiMAx FLIP hardware devices (FLIP 4.0 and FLIP 2.0 detection units) that perform the exhaled air analysis. The LiMAx test is the only non-invasive diagnostic that measures dynamic liver function in real time and is commercially available in Germany, Austria, and the UK.
Differentiator
Problem solved
Functional benefit
Brands
- LiMAx®: The LiMAx® test is the company's flagship product - a non-invasive diagnostic that measures dynamic liver function in real time using 13C-methacetin breath test technology.
Products and services
- LiMAx Test Non-invasive diagnostic that measures dynamic liver function in real time by analyzing exhaled air, providing physicians with a quantitative assessment of an individual patient's liver function capacity within minutes. Indicated for use in liver surgery, transplantation, hepatology, and oncology in hospital and clinical settings.
- LiMAx FLIP 4.0 Detection Unit Detection device that performs the LiMAx breath test by analyzing exhaled air to measure liver function capacity in real time; CE marked for the European market and used by clinical sites performing the LiMAx test.
- LiMAx FLIP 2.0 Detection Unit Detection device used to perform the LiMAx breath test for measuring liver function capacity, representing the prior hardware version of the FLIP platform.
Quantifiable outcome
- More than 20,000 LiMAx tests have been performed
- +2 more outcomes
Companies that use Humedics
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles1 record
Humedics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Humedics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- E-AHPBA-ESSO-ESSR (Innsbruck Consensus Guidelines)coreHumedics participated in the development of the E-AHPBA-ESSO-ESSR Innsbruck consensus guidelines for preoperative liver function assessment before hepatectomy, published in BJS (2023). These guidelines recommend the LiMAx test for preoperative assessment, representing a significant clinical endorsement.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Humedics competitors and assessment
Company assessmentEmerging players
- Genfit: Genfit focuses on diagnostics and therapeutics for NASH and liver diseases, an indication area where LiMAx is expanding. It is an emerging player operating in adjacent liver diagnostic and disease-management space.
Broad incumbents
- Roche Diagnostics: Roche Diagnostics provides comprehensive clinical chemistry and immunoassay platforms used by hospitals for liver function testing. As a broad incumbent it defines the standard workflow LiMAx must integrate with or displace.
- Philips: Philips offers imaging and clinical informatics solutions used in hepatology and liver surgery planning. As a broad incumbent, it provides alternative diagnostic and decision-support capabilities overlapping with LiMAx's use cases.
- Siemens Healthineers: Siemens Healthineers is a large diagnostics incumbent offering broad laboratory and clinical chemistry solutions including liver function panels. It represents the entrenched blood-based testing alternative that LiMAx competes against in hospital workflows.
- GE HealthCare: GE HealthCare provides imaging and diagnostic equipment including ultrasound-based liver assessment tools. It competes broadly in hospital diagnostics where LiMAx is sold.
- Abbott Diagnostics: Abbott offers clinical chemistry analyzers and liver assessment assays used in hospital labs globally. It represents another large incumbent shaping the diagnostic environment in which LiMAx is positioned.
Others
- Labcorp: Labcorp is a major reference laboratory providing liver function and related diagnostic testing services. It is relevant as the existing centralized lab service model against which point-of-care diagnostics like LiMAx position themselves.
- Quest Diagnostics: Quest Diagnostics provides routine and specialty liver diagnostics through its reference lab network. It represents the incumbent centralized testing channel that LiMAx's point-of-care model partially disintermediates.
Direct peers
- Echosens: Echosens markets FibroScan, a non-invasive point-of-care device for liver stiffness and steatosis assessment used in hepatology and liver disease management. It is the most directly comparable non-invasive liver diagnostics competitor to Humedics' LiMAx.
- Exalenz Bioscience (BreathID): Exalenz developed the BreathID 13C-methacetin breath test, which measures liver function using essentially the same substrate as LiMAx, making it a direct technology competitor in non-invasive dynamic liver function diagnostics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Humedics social profiles
Digital presenceHumedics compliance and trust
Trust signalCompliance1 record
Humedics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Humedics leadership team
Management profileNumber of profiles
Profiles9 records
Humedics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Humedics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Humedics
What does Humedics do?
Humedics develops and sells the LiMAx test system, a non-invasive breath-based diagnostic that quantitatively measures dynamic liver function capacity in real time. The offering combines the 13C-methacetin breath test assay with the FLIP detection device (available as FLIP 4.0 and FLIP 2.0) and is CE marked for the European market, sold to university hospitals and medical centers for use in liver surgery, transplantation, hepatology, and oncology.
Is Humedics a public or private company?
Humedics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Humedics founded?
Humedics was founded in 2009. It employs 11 to 50 people.
Where is Humedics based?
Humedics is headquartered in Berlin, Germany, in the Europe region.
How does Humedics make money?
One revenue line is on record: liMAx Test System Sales.
Who are Humedics's main competitors?
Genfit is listed as an emerging player. Broad incumbents are Roche Diagnostics, Philips, Siemens Healthineers, GE HealthCare and Abbott Diagnostics. Others are Labcorp and Quest Diagnostics. Direct peers are Echosens and Exalenz Bioscience (BreathID).
Does Humedics have an API?
No public API is recorded for Humedics.
What industry is Humedics in?
Humedics's product category is Liver Function Diagnostics. Its primary akta.pro industry code is HLAKAEAB, Hepatology & Liver Disease. Its NAICS code is 325413 and its SIC code is 2835.